Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children 1 . 2, 3 . Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation [4] [5] [6] , no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences 7 , suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.
Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors
We performed whole-exome sequencing on 20 rhabdomyosarcoma samples (9 ARMS and 11 ERMS), of which 8 (2 ARMS and 6 ERMS) also underwent whole-transcriptome sequencing. The ages of affected individuals at diagnosis for the ARMS and ERMS tumor samples ranged from 1-25 years and from 1-21 years, respectively (Supplementary Tables 1 and 2 ). Complete tables of variant calls are provided in Supplementary Table 3 . In addition to mutations in RAS genes and FGFR4 seen in ERMS samples and previously reported in this rhabdomyosarcoma subtype 8, 9 , two ERMS tumors had the same c.365T>G point mutation in MYOD1, leading to a p.Leu122Arg substitution ( Fig. 1 and Supplementary Fig. 1 ). Both were primary tumor samples, and, in each case, normal tissue did not harbor the variant, confirming these as somatic mutations. Whole-transcriptome sequencing data were available for one of the two samples with the MYOD1 p.Leu122Arg alteration, and these data showed that the mutant allele was highly expressed (Supplementary Fig. 1 ). MYOD1, as a member of the basic helix-loop-helix (bHLH) family of transcription factors 10 , binds DNA through the basic domain adjacent to its HLH dimerization domain. The p.Leu122Arg alteration occurs in the conserved basic region of MYOD1, at a highly specific, conserved residue that is a leucine in all myogenic bHLH transcription factors, including MYOD1, MYF5, MYOG (myogenin) and MRF4, but is an arginine in MYC family bHLH transcription factors, including MYC and MYCN (Fig. 1) . Remarkably, the MYOD1 Leu122Arg mutant was created experimentally over 20 years ago by Van Antwerp et al., who examined whether altering the MYOD1 basic domain to render it more similar to the MYC basic domain would confer oncogenic properties 7 . They showed that the MYOD1 Leu122Arg mutant bound to a consensus MYOD1 site-competing with wild-type MYOD1 but without leading to MYOD1 target gene transactivation-as well as to a MYC consensus sequence, thereby potentially deregulating the expression of MYC target genes. They hypothesized that this apparent combination of inhibition of differentiation (lack of MYOD1 transactivation) and enhanced proliferation (MYC-like properties) could be a key oncogenic feature of rhabdomyosarcoma 7 .
To better assess the prevalence of the MYOD1 p.Leu122Arg alteration in ERMS tumors, we genotyped another 93 ERMS samples for the corresponding mutation by mass spectrometry-based genotyping (Sequenom). The mutation was detected in 8 additional cases A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations l e t t e r s (and confirmed as somatic in 6 cases with available normal DNA), resulting in an overall prevalence of approximately 10% (10/104; Fig. 1 and Supplementary Fig. 2 ). No MYOD1 mutations were found in 25 ARMS samples (19 fusion positive and 6 fusion negative). To exclude the possibility of analogous leucine-to-arginine alterations in other highly related myogenic factors (MYF5 p.Leu96Arg, MYF6 p.Leu106Arg and MYOG p.Leu94Arg), we screened 101 ERMS samples (from the above set of 104) for such alterations but found none (Fig. 1) .
The ERMS samples harboring the MYOD1 p.Leu122Arg alteration displayed high cellularity and frequent spindle cell morphology, with strong positivity for MYOD1 by immunohistochemistry (Fig. 2) , suggesting in some cases a pathological overlap with the adult spindle cell variant of ERMS 11, 12 . Notably, 9 of 10 ERMS tumors with MYOD1 mutation were from individuals diagnosed in adolescence or adulthood (mean age of 25, median age of 28 at diagnosis), were more likely to arise in the head or neck (8/10 head or neck tumors versus 16/80 tumors at other sites; P = 0.0003) and were somewhat more common in females (8/45 in females versus 2/53 in males; P = 0.04). Furthermore, the overall survival of individuals with MYOD1-mutant ERMS tumors was significantly poorer than for individuals with ERMS tumors lacking MYOD1 mutation (P = 0.02; Fig. 2) .
Previous functional studies on the MYOD1 Leu122Arg mutant had documented effects of the substitution on MYOD1 binding and regulation of model MYOD1 and MYC targets 7 . To extend these data, we first sought to evaluate the effect of the MYOD1 Leu122Arg mutant on myogenic differentiation. We therefore examined morphological differences during the induced differentiation of C2C12 mouse myoblasts in growth factor-deficient medium after retroviral introduction and expression of wild-type MYOD1, MYOD1 Leu122Arg or MYC (Fig. 3a,b) . We observed a higher differentiation index and enhanced muscle cell fusion in C2C12 cells expressing wild-type MYOD1 but not in cells expressing MYOD1 Leu122Arg (Fig. 3a,b) . Consistent with previous data 13 , C2C12 cells expressing MYC could be induced to undergo limited differentiation, but cell fusion was severely inhibited (Fig. 3a,b) . Overexpression of wild-type MYOD1 resulted in reduced growth of C2C12 cells, whereas expression of MYOD1 Leu122Arg did not affect growth in vitro (Fig. 3c) . In soft agar colony formation assays, expression of MYOD1 Leu122Arg increased the number of transformed colonies, although colony size was smaller than that seen for C2C12 cells overexpressing MYC (Fig. 3a,d) . In comparison, when the same experiments were performed in normal growth medium, myogenic differentiation only occurred in C2C12 cells overexpressing wild-type MYOD1 (Supplementary Fig. 3 and Supplementary Note).
In a previous report, we identified PIK3CA mutations in 3 of 60 ERMS samples 8 . Notably, all three of these PIK3CA-mutated tumor samples are among the ten cases encoding MYOD1 p.Leu122Arg identified here ( Table 1) . The relationship between the MYOD1 p.Leu122Arg substitution and PIK3CA mutations appeared significant in the 66 cases with genotyping data for both (PIK3CA mutations in 3/10 cases encoding MYOD1 p.Leu122Arg versus 0/56 cases with wild-type MYOD1; Fisher's exact P = 0.003). The notion that MYOD1 p.Leu122Arg is associated with mutations activating the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway was further strengthened by the finding of two additional MYOD1-mutated ERMS tumors with PTEN deletions ( Table 1 and Supplementary  Fig. 4 ). To assess possible cooperation between these mutations, we examined the effects of the PIK3CA p.His1047Arg and MYOD1 p.Leu122Arg substitutions in C2C12 cells. We introduced GFP, wildtype MYOD1, MYOD1 Leu122Arg and MYC, each in combination with PIK3CA His1047Arg, into C2C12 cells and compared these to C2C12 cells transfected with GFP and control vector (Fig. 4a) . Although the introduction of PIK3CA His1047Arg by itself decreased the differentiation index and the fusion index, these effects were not observed when its expression was combined with that of wild-type MYOD1. However, when PIK3CA His1047Arg was coexpressed with MYOD1 Leu122Arg, differentiation was markedly inhibited (Fig. 4b) . Whereas expression of PIK3CA His1047Arg increased the growth rate of C2C12 cells, regardless of which MYOD1 was expressed, soft agar colony formation assays showed that only the combination of PIK3CA His1047Arg and MYOD1 Leu122Arg resulted in increased colony formation; notably, coexpressing wild-type MYOD1 and PIK3CA 
e t t e r s
His1047Arg did not cause a similar increase in colony number ( Fig. 4c,d ). The negative effect of wild-type MYOD1 on C2C12 cell number and colony formation in the presence of normal medium appears to be due to the induction of differentiation accompanied by cell fusion (Supplementary Fig. 3a) . However, coexpression of PIK3CA His1047Arg and wild-type MYOD1 inhibited myogenic differentiation ( Supplementary Fig. 3c ). We further confirmed the combined effects of PIK3CA His1047Arg and MYOD1 Leu122Arg in C2C12 cells in vivo using cell line xenografts. Whereas the introduction of either MYOD1 Leu122Arg or PIK3CA His1047Arg alone increased the in vivo growth rate of C2C12 cells, the combination of PIK3CA His1047Arg and MYOD1 Leu122Arg resulted in tumors that grew more rapidly (Fig. 4e) . These double-mutant xenograft tumors shared characteristic features of ERMS tumors, such as strong nuclear MYOD1 expression, abundant mitotic activity and high-grade nuclear atypia (Fig. 4f) . As MYOD1 Leu122Arg is likely to function as an aberrant transcription factor, we examined associated gene expression changes. In C2C12 mouse myoblast cells, overlaps among both upregulated and downregulated genes were greater between cells expressing MYOD1 Leu122Arg and MYC than between cells expressing the former and wild-type MYOD1 (P < 0.001 for both upregulated and downregulated genes; Supplementary Fig. 5a ). In BJ human fibroblast cells, the overlap among downregulated genes was greater between cells expressing MYOD1 Leu122Arg and MYC than between cells expressing the former and wild-type MYOD1 (P < 0.001), but the overlap of upregulated genes was not significantly different (P = 0.425) (Supplementary Fig. 5b ). Unsupervised hierarchical clustering placed C2C12 cells with MYOD1 Leu122Arg expression into an independent cluster separate from cells overexpressing MYC and wild-type MYOD1, whereas, in BJ cells, MYOD1 Leu122Arg-expressing cells and MYC-overexpressing cells together formed a cluster separate from cells overexpressing wild-type MYOD1 and parental BJ cells ( Supplementary Fig. 5c,d ). Analysis of muscle differentiation genes within the MYOD1 Leu122Arg expression profiles in C2C12 and BJ cells (Supplementary Tables 4 and 5 , and Supplementary Note) showed that terminal myogenic genes were upregulated by wild-type MYOD1 and downregulated by MYOD1 Leu122Arg (Fig. 5) , consistent with a differentiation block induced by the mutant.
As an alternative approach to examine gene expression relationships, we also used gene set enrichment analysis (GSEA) 14 on the gene list from C2C12 cells expressing MYOD1 Leu122Arg, using the preranked GSEA function and the gene sets of transcription factor targets within the C3: Motif Collection from the Molecular Signature Database 14 . A MYC target gene set was among six gene sets that were significantly enriched in C2C12 cells expressing MYOD1 Leu122Arg (false discovery rate (FDR) q value < 0.1; Supplementary Fig. 6 ). Taken together, these results are consistent These observations raised the possibility of a dominant-negative effect for MYOD1 Leu122Arg. Although loss of heterozygosity (LOH) at 11p15 is frequent in ERMS, our data from Affymetrix OncoScan LOH analysis (Supplementary Fig. 4 ) and comparison Fig. 2 ) together supported loss of the wild-type allele in only five of the ten tumors encoding MYOD1 p.Leu122Arg. This suggested that loss of the wild-type MYOD1 allele was not required. Therefore, to assess whether the MYOD1 Leu122Arg mutant had a dominant-negative effect, we compared the effect of expressing wild-type MYOD1 alone to that of coexpressing it with an equal amount of mutant MYOD1 on the expression of three myogenic genes. Intriguingly, the expression levels of Myh1, Acta1 and Myog were 84%, 61% and 84% lower, respectively, in C2C12 mouse myoblasts expressing both mutant and wild-type MYOD1 compared to cells expressing wild-type MYOD1 alone (Supplementary Fig. 7 ). This finding suggests that, even in the presence of wild-type MYOD1, MYOD1 Leu122Arg can inhibit the expression of myogenic target genes to a supralinear degree, implying that it has a dominant effect. MYOD1 is known to recruit histone-modifying enzymes that increase the levels of monomethylation at lysine 4 of histone H3 (H3K4me1) and acetylation at lysine 27 of histone H3 (H3K27ac) to promote muscle differentiation 15 . Chromatin immunoprecipitation (ChIP) assays in C2C12 cells at three myotube-specific genes 16 (Myl1, Myl2 and Casq2) showed that the frequency of trimethylation at lysine 27 of histone H3 (H3K27me3) and H3K4me1 was increased in the presence of MYOD1 Leu122Arg but not wild-type MYOD1 ( Supplementary Fig. 8 and Supplementary Note). To extend these ChIP data, we performed ChIP sequencing (ChIP-seq) for histone marks in C2C12 cells expressing mutant or wild-type MYOD1. Consistent with the above data from individual ChIP assays, forced expression of MYOD1 Leu122Arg but not wild-type MYOD1 resulted in the emergence of peaks for these marks that were significantly enriched for the 99 differentially regulated genes described above (Supplementary Table 6 and Supplementary Note). Finally, to look for genome-wide evidence of a shift induced by MYOD1 Leu122Arg toward a MYC transcriptional program, we analyzed ChIP-seq data for the activation mark trimethylation at lysine 4 of histone H3 (H3K4me3), comparing ChIP-seq peaks to those previously defined for MYC 17 . This analysis demonstrated that, although both mutant and wild-type MYOD1 were associated with the deposition of H3K4me3 marks at MYC target genes, this effect was stronger for MYOD1 Leu122Arg in a highly significant manner (P < 10 × 10 −15 ; Supplementary Table 7) . These ChIP-seq data for H3K4me3 are therefore in line with the above expression profiling data showing a shift to a MYC-like transcriptional program with the p.Leu122Arg substitution.
Previously described genetic alterations in ERMS tumors include LOH at 11p15 (refs. 18,19) and activating mutations in RAS, FGFR4 and PIK3CA 8, 9, 20 , but none of these define clinically distinct ERMS subsets. In contrast, ERMS tumors with the MYOD1 p.Leu122Arg alteration are distinctive, as they tend to present in older individuals, usually arise in the head or neck, exhibit some overlap pathologically with the recently described spindle cell variant of ERMS and have especially poor outcomes. Indeed, the poor outcomes of individuals with this subtype of ERMS are more similar to outcomes for ARMS than for ERMS. Another parallel with ARMS is the observation that expression of PAX-FOXO1 fusion proteins in myoblasts leads to the suppression of MYOD1 target gene expression 21 , providing a mechanism of how PAX-FOXO1 fusions may lead to differentiation arrest, even as they upregulate the expression of MYOD1 itself 22, 23 . As progression through the different myogenic stages is controlled by the sequential activation of four myogenic factors (MYOD1, MYF5, MYOG and MRF4), PAX-FOXO1 fusion proteins and MYOD1 Leu122Arg may represent alternative mechanisms to disrupt this differentiation program at the MYOD1 stage.
As MYOD1 has long been recognized as a critical regulator of skeletal muscle differentiation 24 , artificial mutations have been used to explore its function, leading to the in vitro identification, over 20 years ago, of the p.Leu122Arg alteration as a neomorphic change 7 . Following up on this in vitro finding, the same group screened for MYOD1 mutations encoding p.Leu122Arg in human rhabdomyosarcoma samples, including 19 primary tumors and 14 cell lines, but found no mutations 25 . Possible reasons that MYOD1 mutations were not identified in this study include the limited number of actual ERMS tumors tested (about 20), misidentification of certain cell lines as rhabdomyosarcoma and fewer tumor samples from individuals diagnosed in late childhood or adulthood.
Although PIK3CA mutations are uncommon in ERMS (occurring in approximately 5% of cases) 8 , we find that they are significantly over-represented in the subset of ERMS tumors encoding MYOD1 p.Leu122Arg. We also observed PTEN intragenic deletions in additional cases. Together with our findings in C2C12 cells expressing MYOD1 Leu122Arg and PIK3CA His1047Arg, these observations suggest cooperation between a transcriptional differentiation block and mutational activation of prosurvival PI3K-AKT signaling, as has recently been established for MYCN and ALK in another major pediatric solid tumor, neuroblastoma 26, 27 . Overall, our data establish ERMS with MYOD1 p.Leu122Arg as a new, molecularly defined subset of rhabdomyosarcoma that should be considered for high-risk protocols and the development of targeted therapeutics.
URLs. R software, http://www.r-project.org/; FASTX-Toolkit, http://hannonlab.cshl.edu/fastx_toolkit/index.html; mouse genome assembly mm10 (full assembly from UCSC), http://genome.ucsc.edu/ cgi-bin/hgGateway?org=Mouse; Picard, http://picard.sourceforge. net/; GSEA, http://www.broadinstitute.org/gsea/index.jsp; Mouse Genome Informatics, http://www.informatics.jax.org/genes.shtml.
METHODS
Methods and any associated references are available in the online version of the paper. 
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We thank H. Hosoi (Kyoto Prefectural University of Medicine) and S. Tanaka and M. Tsuda (both at Hokkaido University) for providing cell lines. We also thank T. Akagi and K. Sasai (both at KAN Research Institute, Inc.) for providing the pcx4bleo plasmid. We are also grateful to J. Zhao for technical assistance with microarray analysis, to L. Borsu for assistance with Sequenom analyses and to E. de Stanchina and R. Tieu for the xenograft studies. Exome capture and high-throughput sequencing. High-quality genomic DNA (2 µg) was captured by hybridization using the SureSelect XT Human All Exon 51Mb kit (Agilent Technologies). Samples were prepared according to the manufacturer's instructions. PCR amplification of the libraries was carried out for six cycles in the pre-capture step and for ten cycles after capture. Samples were barcoded and run on a HiSeq 2000 instrument in a 75-bp/75-bp pairedend run, using the TruSeq SBS Kit v3 (Illumina). An average of 81 million paired reads were generated per sample, the duplication rate varied from 5-11%, and 94% of the targeted region was covered by at least 30×. Illumina HiSeq exome variant calling pipeline. FASTQ files generated by CASAVA bcl2fastq scripts were processed in the default block size of 4,000,000 reads per block. Reads were clipped of adaptor sequences using fastx_clipper from the FASTX-toolkit. Adaptors specific to the R1 and R2 reads were used, and any reads shorter than 50 bp after clipping were discarded. Reads were then trimmed using fastq_quality_trimmer to remove bases with a base quality of less than 3, and reads shorter than 50 bp were dropped. Using a custom Perl script, we repaired reads, and any read whose paired read was discarded in the clipping and trimming phase was moved to a file of single-end reads to be processed separately.
All reads were then mapped to a genome comprising just the assembled chromosomes (chromosomes 1-22, chromosome X, chromosome Y and the mitochondrial chromosome) of build hg19 of the human genome. BurrowsWheeler Aligner (BWA) version 0.5.9-r16 was used. bwa aln was used for both paired-end and single-end reads. SAM files were then created using bwa sampe for paired-end reads and bwa samse for single-end reads. ReadGroups were added at this point, and SAM files were filtered for proper pairing and unique mapping (MAPQ > 0). Blocks were sorted and then merged using Picard MergeSamFiles, and duplicates were removed using Picard MarkDuplicates.
Next, the BAM files for all samples were processed following the Genome Analysis Toolkit (GATK) best-practices guidelines. GATK version 1.6-7 was used. First, BAM files were realigned using GATK RealignerTargetCreator followed by GATK IndelRealigner. These steps were carried out on all samples, with each chromosome processed in parallel. Quality scores were then recalibrated. GATK CountCovariates was run using the following covariates: ReadGroupCovariate, QualityScoreCovariate, CycleCovariate, DinucCovariate, MappingQualityCovariate and MinimumNQSCovariate. Recalibrated BAM files were then computed with GATK TableRecalibration. To call variants, we used the GATK UnifiedGenotyper separately for SNPs and indels. The following options were used. For SNP calling: -stand_call_conf 50.0, -stand_emit_conf 10.0, -dcov 500, -mbq 15; for indel calling: -stand_call_ conf 50.0, -stand_emit_conf 10.0, -dcov 500, -mbq 15.
To filter for somatic events, we used a custom Python script that discards events flagged by GATK as LowQual, and we then filtered for events that were genotyped 0/0 in the normal sample and not at 0/0 in the tumor sample (i.e., at 0/1 or 1/1). We also filtered for a minimum coverage of 2 reads with a given variant (i.e., AD_ALT > 1) in the tumor and a minimum coverage of 2 reads that matched the reference (AD_REF > 1) in the normal sample. We also filtered on the basis of the non-reference allele frequency (NRAF) such that NRAF_TUMOR > NRAF_NORMAL + 0.10, where the tumor had to have an NRAF value 10 percentage points higher than the normal sample. Finally, we retained only events that either changed the amino acid sequence (missense or nonsense variants or any indel targeting an exon) or events that occurred at splice sites.
For the unpaired tumor samples (lacking matched normal tissue), we used the following two subtraction filters. First, we removed events that were called in either of the two normal samples, and, second, we removed any events that were present in a curated version of dbSNP 135. Curation consisted of removing any SNPs from dbSNP that were annotated as having clinical relevance, specifically any SNP that had an OM, CLN, PMC or PM tag in its VCF (variant call format) entry.
Illumina HiSeq RNA sequencing variant calling pipeline. To call variants in RNA sequencing data, we used a custom pipeline based on TopHat and VarScan. Sequence data were mapped using TopHat (v1.4.0) with the transcriptome mapping option on, using the RefSeq gene GTF from UCSC with genes smaller than 150 bp removed. The BAM files from TopHat were processed to make them compatible with VarScan. This consisted of reordering the chromosome header information to match the correct genome order, marking reads with read groups and coordinate sorting the file. We then used SAMtools mpileup with the depth parameter set to 1,000 (−d 1000) and passed the pileup to VarScan (v2.3.2) mpileup2snp. The previous exome calls were then intersected with the RNA sequencing calls, creating a list of events that were present in both data sets. The combined calls were filtered to have a combined depth of at least 10 reads (DP_RNA + DP_EXOME ≥ 10) and were again filtered for events that changed the amino acid sequence. Finally, calls were also filtered against the curated dbSNP 135 database.
Validation samples and Sequenom-based DNA genotyping. Formalin-fixed, paraffin-embedded ERMS samples were procured at the Memorial Sloan Kettering Cancer Center under institutional review board-approved protocols. Additional formalin-fixed, paraffin-embedded ERMS samples were acquired at Brigham and Women's Hospital (J.A.F.) (13 ERMS samples), at University Hospital Gasthuisberg (R.S.) (9 ERMS samples) and at the University of Nebraska Medical Center (J.B.) (6 ERMS samples), under protocols approved by institutional review boards or ethical committees at the respective centers. Mutation validation studies were conducted as a retrospective analysis approved by the Memorial Sloan Kettering Cancer Center Human Biospecimen Utilization Committee and Institutional Review Board. In addition, three ERMS cell lines were included in the set: RD (American Type Culture Collection), RMS559 (from J.A.F.) and the clonally related lines CT-TC (from H. Hosoi) and SMS-CTR (from F.G.B.). These validation samples were studied using the MassARRAY system (Sequenom), which is based on matrix-assisted laser desorption/ionizationtime-of-flight mass spectrometry (MALDI-TOF MS). Genotyping by this method relies on the principle that mutant and wild-type alleles for a given point mutation produce single-allele base-extension reaction products of a mass that is specific to the sequence of the product. Mutation calls are based on the difference in mass between the wild-type product and the mutant products, as resolved by MALDI-TOF MS. Amplification and extension primers were designed using Sequenom Assay Designer v3.1 software to target the curated list of mutations. Amplification primers were designed with a 10-mer tag sequence to increase their mass so that they fell outside the range of detection of MALDI-TOF MS. The sequences of the primers are shown in Supplementary Table 8.
Immunohistochemistry. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections using antibody to MYOD1 (Thermo Scientific, MS-278-P) and a Ventana Immunostainer Discovery XT. After pretreatment (CC1), primary antibody was applied (1:50 dilution) for 90 min. The iView Detection kit (Ventana) was used for detection following the manufacturer's recommendations.
Statistical analysis of survival data. Curves for overall survival (calculated as the time from diagnosis) were constructed using the Kaplan-Meier method and were compared between groups using the log-rank test.
Cell lines. Mouse myoblast cell line C2C12 was purchased from the American Type Culture Collection (CRL-1772). BJ cells expressing the catalytic subunit of human telomerase (hTERT), human diploid foreskin fibroblasts, were kindly provided by S. Tanaka. All cell lines were cultured in DMEM supplemented with 10% FBS (HyClone). Mycoplasma testing is performed on new cell lines received in the laboratory. 
